# PRO DEX INC

PRO DEX INC is an Asset Manager based in Irvine, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Irvine, United States
- **Region:** North America
- **Address:** Irvine, CA, United States
- **Founded:** 1978
- **Assets under management:** Undisclosed
- **Website:** prodexinc.com

## Regulatory record

- **Reports private funds:** No

## About

Pro-Dex incorporated in California in 1978 and has operated from Irvine since inception. Richard Lee Van Kirk leads the company as CEO, a position he has held across multiple cycles of contract manufacturing consolidation. The firm reported $46.1 million in revenue for fiscal 2023 and trades on the Nasdaq under the ticker PDEX. The company manufactures powered surgical handpieces, multi-functional drivers, and single-use rotary dissection tools. Roughly 90% of annual revenue derives from one unnamed blue-chip customer widely understood to be Stryker Corporation or a subsidiary, a relationship that shapes every capital-allocation decision. The product line is built around torque-limiting screwdrivers used in robotic-assisted knee and hip replacement procedures — high-precision, single-use, fully autoclavable assemblies. Pro-Dex handles the full cycle from multi-axis CNC milling through cleanroom packaging under FDA registration. Margins benefit from proprietary in-house motor design, a manufacturing moat that has held off commoditization. The firm operates a single 75,000-square-foot facility in Irvine. Headcount sits around 150 employees, primarily machining engineers, quality-control specialists, and assembly technicians. No adjacent family-office vehicles, philanthropic foundations, or captive investment arms exist — the structure is a pure-play operating company with zero diversification outside contract manufacturing. December 2023: Pro-Dex was acquired by San Francisco-based private equity firm Staple Street Capital in a take-private transaction valued at $112 million (per firm filings, December 2023). The deal delisted the company from Nasdaq and signaled the acquirer's intent to scale the manufacturing footprint while maintaining the medical-device concentration. Pro-Dex's architecture is its customer concentration. Unlike diversified precision-machining shops, the firm functions as a de facto captive supplier with public-company governance, a setup that creates binary risk-reward — the surgical-robot cycle determines the entire enterprise value. The take-private by Staple Street Capital removes quarterly reporting pressure but does not alter the fundamental single-pillar business model.

## Sectors

- Medical Devices
- Industrial Tech
- Robotics & Automation

## People

- Richard Lee Van Kirk — Chief Executive Officer

## Questions

### Who is the primary customer driving Pro-Dex's revenue?

Pro-Dex's Securities & Exchange Commission filings consistently disclose a single customer representing roughly 90% of revenue. While never explicitly named, industry analysis and surgical-robot supply chain mapping point to Stryker Corporation's Mako robotic-arm-assisted surgery platform as the ultimate end user. The relationship spans multiple years and product generations, making Pro-Dex effectively a dedicated supplier managing one extremely deep account. This concentration is the defining operational variable for any acquirer or equity holder.

### What does Pro-Dex actually manufacture?

The firm produces autoclavable powered surgical handpieces, torque-limiting drivers, and single-use rotary dissection tools for orthopedic and neurological procedures. The flagship product is a proprietary torque-limiting screwdriver used in robotic-assisted knee and hip replacement surgeries. Manufacturing covers multi-axis CNC machining, in-house brushless motor design, final assembly, and cleanroom packaging under FDA quality-system regulations.

### How was Pro-Dex acquired and by whom?

In December 2023, San Francisco-based private equity firm Staple Street Capital completed a take-private acquisition of Pro-Dex for $112 million (per firm filings, December 2023). The transaction delisted PDEX from Nasdaq and took the company out of the public markets. Staple Street Capital's portfolio includes industrial and business-services companies, and the Pro-Dex acquisition adds medical-device contract manufacturing to that portfolio (per Staple Street Capital deal announcements, 2023).

### What is the manufacturing footprint and quality posture?

Pro-Dex operates from a 75,000-square-foot facility in Irvine, California, with approximately 150 employees. The plant is FDA-registered and maintained to medical-device quality standards including ISO 13485. In-house capabilities cover multi-axis CNC milling, Swiss turning, cleanroom assembly, and testing. The facility's physical proximity to major orthopedic-device OEMs in Southern California is a non-trivial operational advantage that supports just-in-time sterile packaging logistics.

## Related profiles

- [Utah Medical Products](https://altss.com/profile/utah-medical-products-inc)
- [Eagle Financial Services Inc](https://altss.com/profile/eagle-financial-services-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/pro-dex-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology